tyrosine hydroxylase
Zuletzt aktualisiert 29. Apr 2024
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Ask Patient
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
The TH gene provides instructions for making the enzyme tyrosine hydroxylase, which is important for the normal functioning of the nervous system. Tyrosine hydroxylase takes part in the first step of the pathway that produces a group of chemical messengers called catecholamines.
Normal function
The TH gene provides instructions for making the enzyme tyrosine hydroxylase, which is important for the normal functioning of the nervous system. Tyrosine hydroxylase takes part in the first step of the pathway that produces a group of chemical messengers called catecholamines.
Catecholamines are involved in the autonomic nervous system, which controls involuntary processes such as the regulation of blood pressure and body temperature. Catecholamines are released into the body in response to physical or emotional stress. Catecholamines also transmit signals from brain cells to other cells in the body.
Tyrosine hydroxylase helps convert the protein building block (amino acid) tyrosine to L-DOPA, which can then be converted to dopamine. Other catecholamines called norepinephrine and epinephrine are produced from dopamine.
Conditions referring to this gene or chromosome
Other names
DYT5b
TYH
tyrosine 3-monooxygenase
Related patient information and medicines

Patient information leaflet
Mastozytose und Mastzellenerkrankungen
If the condition is severe, surgery to remove the spleen (splenectomy), medicines that have an effect on ... Dr Sarah Jarvis , 28th September 2021 Midostaurin for treating advanced systemic mastocytosis The National Institute for Health and Care Excellence (NICE) has brought out new guidance on the use of midostaurin for people with mastocytosis..

Patient information leaflet
Mundkrebs
Dia... Dr Krishna Vakharia , 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that a person should receive a diagnosis or ruling out of cancer within 28 days of being referred urgently by their GP for suspected cancer. To confirm the diagnosis It is likely that you will need a biopsy. Cetuximab is an.

Patient information leaflet
Chronische myeloische Leukämie
Treatment for the initial chronic phase The aim of treatment is to control the disease process, to ease any symptoms and to prevent (or delay) the progress... You may be advised to have one or more of the following treatments: Imatinib tablets. This medicine is known as a tyrosine kinase inhibitor. The chemical tyrosine kinase is made by the.

Medicine leaflet
Gefitinib-Tabletten
Gefitinib ist given for lung cancer. Contact your doctor straightaway if you sud... About gefitinib Type of medicine A tyrosine kinase inhibitor chemotherapy medicine Used for Treatment of lung cancer Also called Iressa® Available as Tablets Gefitinib is a medicine which is given to treat some types of lung cancer Lung cancer. In cancer, certain.

Medicine leaflet
Lapatinib-Tabletten
Lapatinib is given for the treatment of breast cancer. About lapatinib Type of medicine A tyrosine kinase inhibitor chemotherapy medicine Used for Treatment of breast cancer Also called Tyverb® Available as Tablets Lapatinib is a medicine which is given for the treatment of breast cancer Breast cancer which has progressed despite other treatment,.

Medicine leaflet
Erlotinib-Tabletten
Erlotinib is given for the treatment of lung cancer, or for the treatment of cancer of the pancreas. Contact your doctor straightaway if you de... About erlotinib Type of medicine A tyrosine kinase inhibitor chemotherapy medicine Used for Lung cancer, and cancer of the pancreas Also called Tarceva® Available as Tablets Erlotinib is a medicine.
Weiterführende Lektüre und Referenzen
- tyrosine hydroxylase; MedlinePlus, National Library of Medicine.
- Furukawa Y, Kish S. Tyrosine Hydroxylase Deficiency. 2008 Feb 8 [updated 2017 May 11]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1437/
- Furukawa Y, Kish SJ, Fahn S. Dopa-responsive dystonia due to mild tyrosine hydroxylase deficiency. Ann Neurol. 2004 Jan;55(1):147-8. doi: 10.1002/ana.10820. No abstract available.
- Hoffmann GF, Assmann B, Brautigam C, Dionisi-Vici C, Haussler M, de Klerk JB, Naumann M, Steenbergen-Spanjers GC, Strassburg HM, Wevers RA. Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia. Ann Neurol. 2003;54 Suppl 6:S56-65. doi: 10.1002/ana.10632.
- Pearl PL, Capp PK, Novotny EJ, Gibson KM. Inherited disorders of neurotransmitters in children and adults. Clin Biochem. 2005 Dec;38(12):1051-8. doi: 10.1016/j.clinbiochem.2005.09.012. Epub 2005 Nov 18.
- Pearl PL, Taylor JL, Trzcinski S, Sokohl A. The pediatric neurotransmitter disorders. J Child Neurol. 2007 May;22(5):606-16. doi: 10.1177/0883073807302619.
- Schiller A, Wevers RA, Steenbergen GC, Blau N, Jung HH. Long-term course of L-dopa-responsive dystonia caused by tyrosine hydroxylase deficiency. Neurology. 2004 Oct 26;63(8):1524-6. doi: 10.1212/01.wnl.0000142083.47927.0a.
- Verbeek MM, Steenbergen-Spanjers GC, Willemsen MA, Hol FA, Smeitink J, Seeger J, Grattan-Smith P, Ryan MM, Hoffmann GF, Donati MA, Blau N, Wevers RA. Mutations in the cyclic adenosine monophosphate response element of the tyrosine hydroxylase gene. Ann Neurol. 2007 Oct;62(4):422-6. doi: 10.1002/ana.21199.
- Yeung WL, Wong VC, Chan KY, Hui J, Fung CW, Yau E, Ko CH, Lam CW, Mak CM, Siu S, Low L. Expanding phenotype and clinical analysis of tyrosine hydroxylase deficiency. J Child Neurol. 2011 Feb;26(2):179-87. doi: 10.1177/0883073810377014. Epub 2010 Sep 7.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
29. Apr 2024 | Neueste Version
1. Mai 2024 | Ursprünglich veröffentlicht
Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.
Abonnieren Sie den Patienten-Newsletter
Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.

